Asahi Kasei Corporation has announced a recommended public offer to the shareholders of Calliditas Therapeutics AB for all the shares in the company, at a price of SEK 208 in cash per share, for a total offer of SEK 11,164 million. The board of directors of Calliditas Therapeutics recommends that the shareholders accept the offer.
KANTER has assisted BVF Partners, Linc AB (publ) and Stiftelsen Industrifonden with certain legal advice in connection with the offer.